Investor Profile: Frazier Life Sciences - Thesis, Cheque Size & How to Apply

Frazier Life Sciences is a Palo Alto headquartered investor backing companies that discover, develop and commercialise innovative biopharmaceuticals, with offices in San Diego, Boston and Seattle and more than 40 professionals. It runs two linked strategies rather than one generalist fund: a venture strategy that creates and backs private companies, and a public equity strategy that supports listed biopharmaceutical companies.

The thesis is product focused. Frazier Life Sciences invests in companies with the potential to generate meaningful human clinical data in trials or to commercialise therapeutics successfully. On the venture side the emphasis is company creation and early private rounds, especially Series A, with a preclinical to clinical focus. The firm seeks meaningful equity ownership, described as more than 20%, and long term partnerships with management teams. That suits scientific founders who want an investor involved before clinical proof, not only after it.

On sectors and stages, the firm is deliberately narrow: biopharmaceuticals only, across company creation, early round privates in Series A, B and C, and public small and mid cap companies. The public strategy also takes part in private crossover rounds. This breadth is a selling point for founders planning a crossover round or a listing, because the same firm can in principle stay involved as the company matures, subject to its own decisions at each stage.

On fund size, Frazier Life Sciences manages over $6.9 billion across venture and public funds. Its venture strategy manages over $4 billion, while its public strategy manages over $2.8 billion. A 2026 report also noted more than $3.6 billion raised across five venture funds since 2016, including $1.3 billion for its venture fund last year. A single standard private cheque size is not publicly disclosed, so founders should not assume a fixed ticket from these totals.

The portfolio record is striking, although deal values below are acquirer prices, not returns to the firm. Verona Pharma was acquired by Merck for $10 billion, Alpine Immune Sciences by Vertex Pharmaceuticals for $4.9 billion, Cerevel Therapeutics by AbbVie for $8.7 billion, Carmot Therapeutics in a $2.7 billion takeover by Roche, and Avidity Biosciences in a $12 billion purchase by Novartis. The firm also highlights Radionetics Oncology, co-created with 5AM Ventures and Crinetics, which signed a Lilly agreement including $140 million upfront. Partners named in recent reporting include Albert Cha, Jamie Brush, Patrick Heron and Jamie Topper. No public accelerator programme or published credits catalogue was found; the value add is scientific diligence, company creation and public market support.

How to apply for funding

There is no single public application portal with a stated form and deadline on the firm's strategy page. Founders normally approach Frazier Life Sciences through frazierls.com, through a warm introduction from a co-investor or academic partner, or through direct contact with the venture team. Lead with the product, disease area, clinical data plan, and what meaningful human data the company can generate next, because that is the test the firm states for its venture investments.